Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

Dupixent is now annualizing at close to €6.0 billion in sales after around five years on the market. Sanofi expects Dupixent to achieve more than €13 billion in peak sales.

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Viking Therapeutics ' ( VKTX 0.28%) shares could rise over the next year by as much as 165% at the midpoint according to some ...

If approved, Dupixent would gain access to an addressable market of at least 75,000 patients. This indication could generate $1.4 billion in annual revenue for Sanofi and Regeneron to split. The ...

Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication. By Zacks Equity Research, Entrepreneur.comJan 21, 2022 ...